metoclopramide medication used stomach esophageal commonly used treat prevent nausea vomiting help emptying stomach people delayed stomach emptying help gastroesophageal reflux also used treat migraine common side effects include feeling tired diarrhea feeling restless serious side effects include neuroleptic malignant syndrome thus rarely recommended people take medication longer twelve evidence harm found taken many pregnant belongs group medications known dopaminereceptor antagonists works metoclopramide one top prescribed medications united available generic world health organizations list essential commonly prescribed medication united states metoclopramide commonly used treat nausea vomiting associated conditions uremia radiation sickness cancer effects chemotherapy labor infection emetogenic perioperative antiemetic effective dose usually mg compared usual mg dose also used pregnancy second choice treatment hyperemesis gravidarum severe nausea vomiting also used preventatively ems providers transporting people conscious spinally migraine headaches metoclopramide may used combination paracetamol acetaminophen combination evidence also supports use gastroparesis condition causes stomach empty poorly drug approved fda also used gastroesophageal reflux metoclopramide used try increase breast milk production evidence effectiveness safety use also intravenous metoclopramide used smallbowel followthrough smallbowel enema radionuclide gastricemptying studies reduce time taken barium go intestines thus reducing total time needed procedures metoclopramide also prevents vomiting oral ingestion metoclopramide contraindicated pheochromocytoma used caution parkinsons disease since dopamine antagonist may worsen symptoms longterm use avoided people clinical depression may worsen ones mental contraindicated people suspected bowel epilepsy stomach operation performed previous three four days perforation blockage stomach newborn safety drug reviewed european medicines agency determined prescribed high doses periods five days given children year age suggested use older children restricted treating postchemotherapy postsurgery nausea vomiting even patients treatments failed adults recommended use restricted treating migraines postchemotherapy postsurgery metoclopramide long used stages pregnancy evidence harm mother large cohort study babies born israeli women exposed metoclopramide pregnancy found evidence drug increases risk congenital malformations low birth weight preterm birth perinatal large cohort study denmark found addition association metoclopramide exposure metoclopramide excreted systematic review found wide range reported outcomes treatment gastroesophageal reflux disease gerd infants concluded poor rating evidence inconclusive rating safety efficacy treatment gerd common adverse drug reactions adrs associated metoclopramide therapy include restlessness akathisia focal dystonia infrequent adrs include hypertension hypotension hyperprolactinaemia leading galactorrhea headache extrapyramidal effects oculogyric metoclopramide may common cause druginduced movement risk extrapyramidal effects increased people years age highdose prolonged tardive dyskinesia may persistent irreversible people majority reports tardive dyskinesia occur people used metoclopramide three consequently us food drug administration fda recommends metoclopramide used shortterm treatment preferably less weeks fda required manufacturers metoclopramide issue black box warning regarding risk tardive dyskinesia chronic highdose use dystonic reactions may treated benzatropine diphenhydramine trihexyphenidyl procyclidine symptoms usually subside diphenhydramine injected agents benzodiazepine class drugs may helpful benefits usually modest side effects sedation weakness cases akathisia effects metoclopramide directly related infusion rate drug administered intravenously side effects usually seen first min dose diabetes age female gender risk factors increase likelihood experiencing neuropsychiatric side effect metoclopramide appears bind dopamine receptors nanomolar affinity ki receptor antagonist also mixed receptor receptor antiemetic action metoclopramide due antagonist activity receptors chemoreceptor trigger zone central nervous system action prevents nausea vomiting triggered higher doses antagonist activity may also contribute antiemetic verification gastroprokinetic activity metoclopramide mediated muscarinic activity receptor antagonist activity receptor agonist gastroprokinetic effect may also contribute antiemetic effectcitation needed metoclopramide also increases tone lower esophageal metoclopramide might influence mood antagonistic blockade agonistic activating action metoclopramide substituted benzamide cisapride mosapride structurally metoclopramide first described louis justinbesançon charles laville working improve antidysrhythmic properties research project also produced product first clinical trials published tourneu et al boisson albot justinbesançon laville worked laboratoires company introduced drug primperan laboratoires delagrange acquired synthelabo eventually became part ah robins introduced drug us brand name reglan oral form approved ah robins acquired american home changed name wyeth drugs initially used control nausea people severe headaches migraines later uses nausea caused radiation therapy chemotherapy later yet treating nausea caused us injectable form labelled chemotherapyinduced nausea oral form eventually labelled gastroesophageal reflux became widely used becoming commonly used drug treat anesthesiainduced treating gastritis emergency first generics introduced early signs began emerge pharmacovigilance studies sweden drug causing tardive dyskinesia fda required warning tardive dyskinesia added drug label stating tardive dyskinesia may develop patients treated metoclopramide warned use longer weeks long drug fda required black box warning added emergence severe side effect led wave product liability litigation generic manufacturers well litigation complicated since lack clarity jurisdiction state laws product liability determined federal law determines drugs labelled well generics companies control labelling originator company litigation yielded least two important cases conte v wyeth california state courts claims plaintiff generic companies pliva teva purepac sold drugs plaintiff actually took claims wyeth whose product plaintiff never took dismissed trial court case appealed appellate court upheld dismissal cases generic companies reversed wyeth allowing case wyeth established innovator liability pioneer liability pharmaceutical precedent widely followed california litigation issues related metoclopramide also reached us supreme court pliva inc v court held generic companies held liable information lack information originators august suits pending across us efforts consolidate class action failedcitation needed shortly following pliva decision fda proposed rule change would allow generics manufacturers update label originating drug withdrawn market reasons may rule turned controversial since would open generic companies product liability suits still finalized fda stated final rule would issued april fda issued draft guidance generic companies update labels july metoclopramide commonly used prevent vomiting cats dogs also used gut stimulant httpsenwikipediaorgwikimetoclopramide